Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented- constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.
Currently, the IBS treatment market is na?ve and underpenetrated, with 4 products indicated for IBS in the market. These include the IBS-C therapies, Amitiza (lubiprostone, Sucampo/Takeda) and Linzess (linaclotide, Ironwood/Allergan/Astellas); and the IBS-D therapies, Lotronex (Sebela Pharmaceuticals) and Irribow (ramosetron, Astellas). Antidepressants and antibiotics (mainly Xifaxan [rifaximin], Valeant) are also used off-label to treat IBS.
The IBS treatment market is characterized by significant unmet needs, which include the need for products with improved efficacy, products for the treatment of the IBS-D and IBS-M subtypes, and products that effectively address IBS symptoms, such as abdominal pain and bloating, as well as the requirement for the improved diagnosis of IBS. As a result, there are significant opportunities in the uncrowded IBS therapeutics market.

According to this study, over the next five years the Irritable Bowel Syndrome (IBS) market will register a 16.3% CAGR in terms of revenue, the global market size will reach USD 6530 million by 2024, from USD 2640 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Irritable Bowel Syndrome (IBS) business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Irritable Bowel Syndrome (IBS) market by product type, application, key manufacturers and key regions and countries.

This study considers the Irritable Bowel Syndrome (IBS) value and volume generated from the sales of the following segments-

Segmentation by product type- breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
IBS-D Drug
IBS-C Drug
Other
Segmentation by application- breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Women
Men

This report also splits the market by region- Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report- Breakdown data in in Chapter 3.
Allergan
Valeant Pharmaceuticals
Takeda
Sucampo Pharmaceuticals
McNeil Consumer Healthcare
Sebela Pharmaceuticals
Astellas Pharmaceuticals
IM HealthScience

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Irritable Bowel Syndrome (IBS) consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Irritable Bowel Syndrome (IBS) market by identifying its various subsegments.
Focuses on the key global Irritable Bowel Syndrome (IBS) manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Irritable Bowel Syndrome (IBS) with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Irritable Bowel Syndrome (IBS) submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.